Literature DB >> 8315392

Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.

P Hwu1, G E Shafer, J Treisman, D G Schindler, G Gross, R Cowherd, S A Rosenberg, Z Eshhar.   

Abstract

To expand the spectrum of recognition of effector lymphocytes and to redirect them towards predefined targets, we have altered the specificity of human tumor-infiltrating lymphocytes (TIL) through stable modification with chimeric receptor genes consisting of single-chain antibody variable regions linked to the gamma subunit common to the immunoglobulin (Ig)G and IgE Fc receptors. Using either hapten or ovarian carcinoma-specific monoclonal antibodies, we constructed chimeric receptor genes and retrovirally introduced them into CD8+ TIL. Redirected TIL specifically lysed trinitrophenyl-labeled Daudi or a human ovarian carcinoma cell line (IGROV-1), and secreted granulocyte/macrophage colony-stimulating factor upon stimulation with the appropriate antigen. This strategy may allow new approaches towards the adoptive immunotherapy of cancer in humans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8315392      PMCID: PMC2191075          DOI: 10.1084/jem.178.1.361

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  33 in total

1.  Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production.

Authors:  A D Miller; C Buttimore
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

2.  Hybrid antibodies can target sites for attack by T cells.

Authors:  U D Staerz; O Kanagawa; M J Bevan
Journal:  Nature       Date:  1985 Apr 18-24       Impact factor: 49.962

3.  Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.

Authors:  L M Muul; P J Spiess; E P Director; S A Rosenberg
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

4.  Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion.

Authors:  G Köhler; C Milstein
Journal:  Eur J Immunol       Date:  1976-07       Impact factor: 5.532

5.  Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.

Authors:  S L Topalian; L M Muul; D Solomon; S A Rosenberg
Journal:  J Immunol Methods       Date:  1987-08-24       Impact factor: 2.303

6.  Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice.

Authors:  J Bénard; J Da Silva; M C De Blois; P Boyer; P Duvillard; E Chiric; G Riou
Journal:  Cancer Res       Date:  1985-10       Impact factor: 12.701

7.  Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody.

Authors:  P Perez; R W Hoffman; S Shaw; J A Bluestone; D M Segal
Journal:  Nature       Date:  1985 Jul 25-31       Impact factor: 49.962

8.  Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans.

Authors:  P Hwu; J Yannelli; M Kriegler; W F Anderson; C Perez; Y Chiang; S Schwarz; R Cowherd; C Delgado; J Mulé
Journal:  J Immunol       Date:  1993-05-01       Impact factor: 5.422

9.  Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions.

Authors:  Y Kuwana; Y Asakura; N Utsunomiya; M Nakanishi; Y Arata; S Itoh; F Nagase; Y Kurosawa
Journal:  Biochem Biophys Res Commun       Date:  1987-12-31       Impact factor: 3.575

10.  Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity.

Authors:  S Miotti; S Canevari; S Ménard; D Mezzanzanica; G Porro; S M Pupa; M Regazzoni; E Tagliabue; M I Colnaghi
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

View more
  54 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

2.  Simplified process for the production of anti-CD19-CAR-engineered T cells.

Authors:  Barbara Tumaini; Daniel W Lee; Tasha Lin; Luciano Castiello; David F Stroncek; Crystal Mackall; Alan Wayne; Marianna Sabatino
Journal:  Cytotherapy       Date:  2013-08-28       Impact factor: 5.414

Review 3.  Recent advances and discoveries in the mechanisms and functions of CAR T cells.

Authors:  Rebecca C Larson; Marcela V Maus
Journal:  Nat Rev Cancer       Date:  2021-01-22       Impact factor: 60.716

4.  Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.

Authors:  James N Kochenderfer; Steven A Feldman; Yangbing Zhao; Hui Xu; Mary A Black; Richard A Morgan; Wyndham H Wilson; Steven A Rosenberg
Journal:  J Immunother       Date:  2009-09       Impact factor: 4.456

Review 5.  Immunotherapy II: Antigens, receptors and costimulation.

Authors:  P F Searle; L S Young
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 6.  The T-body approach: potential for cancer immunotherapy.

Authors:  Z Eshhar; N Bach; C J Fitzer-Attas; G Gross; J Lustgarten; T Waks; D G Schindler
Journal:  Springer Semin Immunopathol       Date:  1996

Review 7.  Targeting of peripheral blood T lymphocytes.

Authors:  R L Bolhuis; H R Hoogenboom; J W Gratama
Journal:  Springer Semin Immunopathol       Date:  1996

Review 8.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 9.  Advances in the development of cancer immunotherapies.

Authors:  Jianjun Gao; Chantale Bernatchez; Padmanee Sharma; Laszlo G Radvanyi; Patrick Hwu
Journal:  Trends Immunol       Date:  2012-09-30       Impact factor: 16.687

Review 10.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.